Table of Contents
Diagnostic breakthroughs for neurodegenerative diseases (TechVision) : R&D Portfolio Analysis of Neurodiagnostic Innovations
This research service covers key technological trends and developments in diagnostics for neurodegenerative diseases, which are likely to have a high impact in the near future. The technologies present across the global neurodiagnostic industry have been covered under neurobiomarkers, neuroimaging and neuroinformatics segments. While providing brief overviews for each technology, the research service also covers industrial snapshots and emerging innovations in the neurodiagnostic markets. The research service also includes drivers & challenges, market adoption, collaborations, funding and patent scenarios for neurodiagnostic technologies.
Key Findings : Global Neurodiagnostics Segment
Neuroimaging technologies continue to remain the gold-standard for neurodiagnostic applications and they constitute the largest market segment in this space. Advancements in this sector encompass the emergence of novel hybrid imaging technologies that offer smooth work flow integration across various imaging modalities and software analysis platforms. Another significant trend in this space is the development of novel radiotracers for neurological biomarkers that aid diagnostic and clinical applications for diseases such as Alzheimer’s Disease (AD).
There are several assay platforms that are currently available for the detection of neurological biomarkers, especially for diseases such as dementia and AD. However, new biomarker discoveries and advanced diagnostic platforms for Parkinson’s disease (PD), traumatic brain injury (TBI), and other dementias are expected in the near future. Emerging technological trends in this sector include the use of optical scanning techniques for detecting retinal biomarkers for neurological diseases.
While there are several software platforms that are available for processing neuroimaging data, limited algorithms are currently available for diagnostic and clinical analyses. There are, however, several cloud-based storage platforms for exchange and analyses of a vast amount global neurological data. Furthermore, as more companies are looking to develop quantitative software techniques for the detection and analyses of various neuropathologies, this sector is optimally poised for a major growth spurt in the near future.
Increasing collaborations across the pharmaceutical and diagnostic segments are fueling the growth of companion diagnostic market for neurological disorders, thus setting the stage for wider market outreach. Such collaborations for patient selection during clinical trials are likely to mirror the growth phase observed for the cancer companion diagnostics marke
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Lewy Body Dementia in 12 Major Markets Dementia with Lewy Bodies (DLB) is the second most frequent cause of age related neurodegenerative ...
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Alzheimer’s disease in 12 Major Markets Alzheimer's disease (AD) is a progressive, irreversible neurodegenerative disorder. It is ...